GV-971 treatment for mild to moderate Alzheimer’s disease
Part of Brain & nervous system, Mental health clinical trials.
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Alzheimer’s disease that is mild to moderate
- Your thinking or daily functioning has been getting worse for at least 1 year
- Your memory test score (MMSE) is between 11 and 24 (inclusive)
- You do not have signs of a brain condition that is more likely stroke-related or another type of dementia
- You can complete study visits with a reliable caregiver or study partner
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called GV1001, given as a small injection under the skin, to see if it can help slow down memory and thinking problems in people with moderate to severe Alzheimer's disease. The trial lasts for a period of time and involves regular check-ups and cognitive tests.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.